Transcatheter Valve

Transcatheter Valve Market Outlook

The global Transcatheter Valve Market is poised for significant growth, projected to reach USD 8.4 billion by 2035, expanding at a CAGR of approximately 14.2% from 2025 to 2035. The growth of this market is primarily driven by an increasing prevalence of valvular heart diseases and a rising geriatric population, necessitating innovative treatment options. Furthermore, technological advancements in transcatheter valve procedures, coupled with improved patient outcomes and lesser recovery times compared to traditional surgical approaches, are also contributing to the market's expansion. Increased healthcare expenditure and the growing adoption of minimally invasive procedures are further catalyzing the demand for transcatheter valves across various healthcare settings. As a result, the market is expected to witness a robust upward trajectory in the coming years.

Growth Factor of the Market

The Transcatheter Valve Market is experiencing substantial growth underpinned by several key factors. The increasing incidence of heart valve diseases, such as aortic stenosis and mitral regurgitation, is driving the demand for effective transcatheter interventions. With a growing aging population that is more susceptible to heart conditions, healthcare systems worldwide are seeking efficient and less invasive solutions that can improve patient outcomes. Technological advancements in transcatheter valve devices, such as enhanced imaging techniques and improved valve designs, are also contributing significantly to market growth. Additionally, favorable reimbursement policies and increasing investments into cardiovascular research and development are creating a conducive environment for market expansion. The rise in patient awareness regarding the advantages of minimally invasive surgeries is further propelling the adoption of transcatheter valve procedures.

Key Highlights of the Market

• Increasing demand for minimally invasive surgical options in cardiac interventions.
• Technological advancements in valve design and delivery systems.
• Growing prevalence of valvular heart diseases among the aging population.
• Favorable reimbursement policies supporting transcatheter procedures.
• Increased investments in cardiovascular research and innovation.

By Product Type

Transcatheter Aortic Valve:

The Transcatheter Aortic Valve segment is one of the most prominent in the market, primarily due to the increasing prevalence of aortic stenosis, which significantly impacts the elderly population. This type of valve provides a less invasive option for patients who are considered high-risk for traditional surgical valve replacement. The ease of deployment and minimal recovery time associated with transcatheter aortic valves has led to their rising acceptance among healthcare providers and patients alike. Furthermore, ongoing clinical studies and trials are exploring the efficacy and safety of these valves, which is expected to bolster their market presence significantly over the forecast period.

Transcatheter Mitral Valve:

The Transcatheter Mitral Valve segment is gaining momentum as it addresses the growing need for effective management of mitral valve diseases, particularly mitral regurgitation. The innovative design of these valves allows for easier implantation and better functional outcomes. This has made them a preferred choice not only for high-risk patients but also for those who might benefit from less invasive procedures. The increasing awareness among physicians regarding the advantages of transcatheter mitral valve therapies is also contributing to the market growth in this segment, along with advancements in surgical techniques and devices.

Transcatheter Pulmonary Valve:

Transcatheter Pulmonary Valves have emerged as a critical option for patients with congenital heart defects and other related conditions. The growing recognition of their efficacy in treating pulmonary valve dysfunction is propelling their adoption. These valves are particularly advantageous for younger patients, as they can be delivered via catheter and do not require open-heart surgery, leading to significantly reduced recovery times. Moreover, advancements in valve materials and designs are enhancing the durability and performance of these transcatheter pulmonary valves, attracting more healthcare facilities to incorporate them into their treatment protocols.

Transcatheter Tricuspid Valve:

The Transcatheter Tricuspid Valve segment is gaining traction, primarily due to the increasing incidence of tricuspid regurgitation, which often remains undiagnosed and untreated. The development of transcatheter solutions for this valve type is relatively new, but it holds promise for addressing the unmet needs of patients who are not candidates for conventional surgery. Ongoing clinical trials are revealing positive outcomes, contributing to the growing interest and investment in this segment. Furthermore, the advancements in transcatheter delivery systems are facilitating the more widespread adoption of these valves in clinical practice.

Transcatheter Combo Valve:

Transcatheter Combo Valves are an innovative approach that combines multiple functionalities, addressing several valvular conditions simultaneously. This segment is particularly appealing due to its ability to streamline treatment processes for patients requiring multiple interventions. The demand for combo valves is expected to rise as healthcare practitioners aim to provide comprehensive care options for patients with complex cardiovascular conditions. These advances in valve technology, along with positive clinical outcomes, are likely to drive the growth of the transcatheter combo valve market.

By Application

Transcatheter Aortic Valve Replacement (TAVR):

The application of Transcatheter Aortic Valve Replacement (TAVR) is increasingly recognized for its role in treating severe aortic stenosis in patients who are at increased surgical risk. This minimally invasive procedure allows for effective valve replacement without the need for traditional open-heart surgery, leading to shorter recovery times and improved patient comfort. The growing body of evidence supporting the long-term safety and efficacy of TAVR is driving its widespread adoption across healthcare settings. As more healthcare providers become trained in this technique, the demand for TAVR procedures is projected to surge in the coming years.

Transcatheter Mitral Valve Repair (TMVR):

Transcatheter Mitral Valve Repair (TMVR) is an essential application that is gaining traction due to its effectiveness in treating mitral regurgitation. This procedure offers a less invasive option for patients who may not be suitable candidates for surgical intervention. The TMVR market is rapidly evolving, with ongoing research focused on improving device designs and techniques to enhance outcomes. The increasing awareness and acceptance of TMVR as a viable treatment option among cardiologists are expected to significantly impact its market growth positively.

Transcatheter Pulmonary Valve Replacement:

The application of Transcatheter Pulmonary Valve Replacement is critical for patients with congenital heart defects and other pulmonary valve-related conditions. This procedure allows for the replacement of dysfunctional valves through a catheter-based approach, which is particularly beneficial for children and adolescents. The growing pediatric population requiring pulmonary valve interventions is expected to drive market growth in this application. Additionally, advancements in valve technology and design are further enhancing the performance and reliability of transcatheter pulmonary valve replacements.

Transcatheter Tricuspid Valve Repair:

Transcatheter Tricuspid Valve Repair is a developing application addressing the needs of patients suffering from tricuspid regurgitation. The ability to repair the valve with minimal invasiveness presents a significant advantage for patients who are often elderly and may have comorbidities that complicate traditional surgical options. As more clinical evidence emerges supporting the safety and efficacy of transcatheter tricuspid valve procedures, their adoption is expected to increase. This segment holds promise for addressing a significant unmet medical need and is likely to witness steady growth in the coming years.

Transcatheter Combo Valve Procedures:

Transcatheter Combo Valve Procedures represent an innovative approach to treating multiple valvular conditions simultaneously. This application is particularly advantageous for high-risk patients who may require interventions on more than one valve. By combining procedures, healthcare providers can optimize treatment plans and improve overall patient outcomes. The increasing research and development efforts in this area are expected to enhance the efficacy of combo valve procedures, thereby driving their adoption within interventional cardiology practices.

By Distribution Channel

Hospitals:

The hospital distribution channel is a cornerstone of the Transcatheter Valve Market, accounting for a significant share due to the high volume of cases treated in these settings. Hospitals often have the necessary resources and specialized staff for performing complex transcatheter procedures, making them the preferred location for valve interventions. Moreover, hospitals are increasingly adopting advanced technologies and techniques, contributing to improved patient outcomes. The rising number of hospitalizations for cardiovascular diseases is also bolstering market growth in this distribution channel.

Cardiac Centers:

Cardiac centers are specialized facilities dedicated to the diagnosis and treatment of heart-related conditions, playing a vital role in the Transcatheter Valve Market. These centers often have the latest technology and expertise in performing complex cardiac procedures, including transcatheter valve interventions. The growing trend of patients seeking specialized care for cardiovascular diseases is leading to an increase in the establishment and utilization of cardiac centers. As a result, this distribution channel is expected to see a significant rise in patient volume and procedure frequency.

Ambulatory Surgical Centers:

Ambulatory Surgical Centers (ASCs) are increasingly becoming a popular choice for transcatheter valve procedures due to their efficiency and cost-effectiveness. These facilities allow patients to undergo procedures and return home on the same day, significantly enhancing patient satisfaction. The growing preference for outpatient procedures is driving the adoption of ASCs for transcatheter valve interventions. Furthermore, the ability to perform minimally invasive procedures in an ASC setting is attracting both patients and healthcare providers, thereby contributing to the overall growth of this distribution channel.

Specialty Clinics:

Specialty clinics focusing on cardiovascular care are emerging as an important distribution channel within the Transcatheter Valve Market. These clinics provide targeted care and often employ advanced technologies to perform transcatheter procedures. The increasing number of these clinics is driven by the rising demand for specialized cardiac care and the desire for more personalized treatment options. As specialty clinics continue to expand their services, they are likely to play a significant role in the market's growth and provide alternatives for patients who may not require hospital admission for their procedures.

Online Sales:

The online sales distribution channel is gradually making its presence felt in the Transcatheter Valve Market, particularly in terms of educational resources and medical equipment sales. As healthcare providers increasingly turn to digital platforms for training and purchasing supplies, the demand for online resources is expected to rise. While direct online sales of medical devices are still limited due to regulatory restrictions, the potential for growth in this area is significant. Online platforms can facilitate access to innovative valve technologies and educational materials, ultimately enhancing the market's dynamics.

By Material Type

Metal Valve:

Metal valves represent a crucial segment in the Transcatheter Valve Market, known for their durability and longevity. These valves are typically made from materials like stainless steel or cobalt-chromium, which offer excellent mechanical support and resistance to wear and tear. The adoption of metal valves is largely driven by their strong performance in high-pressure environments, making them suitable for patients with specific cardiovascular conditions. As practitioners continue to emphasize long-term outcomes, the demand for metal valves is expected to remain strong in various transcatheter procedures.

Tissue Valve:

Tissue valves are increasingly gaining traction in the market due to their favorable biocompatibility and aesthetic benefits. These valves are constructed from animal tissues and are designed to mimic the natural function of human valves, making them an attractive option for many patients. The demand for tissue valves is on the rise, particularly among those requiring transcatheter procedures, as they often present a lower risk of thrombosis compared to metal valves. The ongoing advancements in tissue preservation and valve design are expected to further enhance the acceptance of tissue valves in clinical practice.

Transcatheter Valve with Hybrid Material:

Transcatheter valves constructed with hybrid materials are at the forefront of innovation in the market, combining the favorable properties of both metal and tissue components. These hybrid valves aim to provide the optimal balance between durability and biocompatibility, addressing the limitations associated with traditional valve types. The increasing complexity of cardiovascular diseases necessitates the development of versatile valve solutions, which is driving the interest and investment in hybrid materials. As clinical outcomes continue to improve, hybrid valves are anticipated to gain a more significant market share in the transcatheter valve sector.

By Region

The Transcatheter Valve Market exhibits distinct regional dynamics, with North America holding the largest share, valued at approximately USD 3 billion in 2025. This region's dominance can be attributed to advanced healthcare infrastructure, a high prevalence of heart diseases, and significant investments in cardiovascular research. Moreover, the introduction of favorable reimbursement policies and increasing adoption of minimally invasive procedures are further boosting the market in North America. The CAGR for this region is estimated at 14.0%, reflecting a robust growth trajectory driven by ongoing technological advancements and increasing awareness among patients and healthcare professionals.

Europe is another key region in the Transcatheter Valve Market, expected to reach USD 2.5 billion by 2035, growing at a CAGR of 13.5% from 2025 to 2035. The expansion in this region is supported by a growing elderly population and rising healthcare expenditures, leading to increased demand for innovative cardiovascular treatments. Emerging markets in Asia Pacific are also witnessing a significant increase in market activity, projected to reach USD 1.8 billion by 2035, fueled by improvements in healthcare access and rising patient awareness about transcatheter procedures. However, other regions like Latin America and the Middle East & Africa are still in the nascent stages of market development, accounting for a smaller share but showing promising growth potential due to increasing healthcare investments and infrastructural developments.

Opportunities

The Transcatheter Valve Market is ripe with opportunities, particularly due to the ongoing advancements in valve technology and delivery systems. Innovations such as improved imaging techniques, patient-specific valve designs, and enhanced surgical instruments are expected to significantly enhance the safety and efficacy of transcatheter procedures. This technological evolution not only facilitates better patient outcomes but also encourages healthcare providers to adopt these procedures more widely. Furthermore, the increasing focus on preventive healthcare and early diagnosis of cardiovascular diseases presents a substantial opportunity for market players to introduce innovative solutions tailored to meet the evolving needs of patients and clinicians alike. As reimbursement policies continue to evolve, there is a further opportunity for market expansion as healthcare systems recognize the long-term cost benefits associated with transcatheter valve procedures.

In addition to technological advancements, global demographic trends are creating new opportunities for growth within the Transcatheter Valve Market. The aging global population is leading to a higher incidence of heart valve diseases, necessitating the development of accessible and effective treatment options. As more individuals are diagnosed with valvular heart diseases, there will be an increased demand for transcatheter interventions, driving market growth. Market participants can capitalize on these trends by expanding their product portfolios and entering new geographic regions that are experiencing rapid healthcare development. Moreover, strategic partnerships and collaborations among healthcare providers, device manufacturers, and research institutions can accelerate the introduction of innovative solutions, further enhancing market opportunities.

Threats

Despite the positive outlook for the Transcatheter Valve Market, several threats could impede its growth. One of the primary challenges is the stringent regulatory environment governing medical devices, which can delay the approval and commercialization of new products. The need to comply with rigorous testing and quality standards may limit the speed at which innovations enter the market, potentially hindering the growth of companies involved in the development of transcatheter valves. Additionally, the presence of established competitors with a strong foothold in the market can pose a significant threat to smaller, emerging companies seeking to penetrate this space. Intense competition may lead to price wars, affecting profit margins and overall market viability.

Another concerning issue is the potential for clinical complications associated with transcatheter procedures, such as valve migration, thromboembolic events, and paravalvular leaks. Adverse outcomes can not only diminish patient trust but also lead to increased healthcare costs associated with follow-up interventions. Furthermore, economic fluctuations and uncertainties in healthcare funding can impact the availability of resources needed for ongoing cardiovascular research and development. Patients' reluctance to adopt new technologies due to lack of awareness or resistance to change also presents a challenge. Addressing these threats will require concerted efforts from industry stakeholders to enhance product education, improve patient outcomes, and navigate the regulatory landscape effectively.

Competitor Outlook

• Edwards Lifesciences Corporation
• Boston Scientific Corporation
• Medtronic plc
• Abbott Laboratories
• Cardinal Health, Inc.
• JenaValve Technology, Inc.
• Symetis SA
• Micro Interventional Devices, Inc.
• Direct Flow Medical, Inc.
• Neovasc Inc.
• St. Jude Medical, Inc.
• TERUMO Corporation
• Cryolife, Inc.
• Direct Flow Medical, Inc.
• Vascular Innovations

The competitive landscape of the Transcatheter Valve Market is characterized by the presence of several established players and emerging companies dedicated to advancing cardiac care. Major companies like Edwards Lifesciences and Medtronic continue to dominate the market due to their innovative product offerings and extensive distribution networks. These firms invest heavily in research and development to enhance their existing product lines and to introduce groundbreaking innovations that cater to the evolving needs of healthcare providers and patients. The competitive rivalry is further intensified by the increasing number of product approvals and the launch of advanced devices, which contributes to an ever-evolving market landscape. Additionally, companies are focusing on strategic alliances, partnerships, and acquisitions to consolidate their market position and expand their geographic footprint.

For instance, Edwards Lifesciences Corporation is a leader in the transcatheter heart valve segment, known for its innovative TAVR solutions. The company has made significant investments in clinical trials to validate the long-term efficacy and safety of its products, thereby enhancing its credibility in the market. Medtronic plc has also made strides in this space with a diverse portfolio, including transcatheter aortic and mitral valve solutions. Their commitment to research and innovation has enabled them to remain competitive while addressing the unique needs of patients requiring advanced cardiac interventions. Furthermore, Boston Scientific Corporation is another key player that continues to make strategic investments in the development of transcatheter valve technologies, enhancing its product offerings and driving market growth.

Emerging companies such as JenaValve Technology and Micro Interventional Devices are also making significant contributions to the market by introducing novel solutions that address specific patient needs. These innovators are leveraging advancements in technology to develop next-generation transcatheter valves that promise improved outcomes and patient satisfaction. As these companies continue to expand their research capabilities and clinical trial initiatives, they are likely to carve out a substantial niche within the market. Overall, the competitive landscape of the Transcatheter Valve Market is dynamic, with established players and new entrants continuously striving to differentiate themselves through innovation, quality, and patient outcomes.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Symetis SA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Neovasc Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic plc
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Cryolife, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 TERUMO Corporation
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Abbott Laboratories
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Vascular Innovations
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Cardinal Health, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 St. Jude Medical, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Direct Flow Medical, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 JenaValve Technology, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boston Scientific Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Edwards Lifesciences Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Micro Interventional Devices, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Transcatheter Valve Market, By Application
    • 6.1.1 Transcatheter Aortic Valve Replacement (TAVR)
    • 6.1.2 Transcatheter Mitral Valve Repair (TMVR)
    • 6.1.3 Transcatheter Pulmonary Valve Replacement
    • 6.1.4 Transcatheter Tricuspid Valve Repair
    • 6.1.5 Transcatheter Combo Valve Procedures
  • 6.2 Transcatheter Valve Market, By Product Type
    • 6.2.1 Transcatheter Aortic Valve
    • 6.2.2 Transcatheter Mitral Valve
    • 6.2.3 Transcatheter Pulmonary Valve
    • 6.2.4 Transcatheter Tricuspid Valve
    • 6.2.5 Transcatheter Combo Valve
  • 6.3 Transcatheter Valve Market, By Material Type
    • 6.3.1 Metal Valve
    • 6.3.2 Tissue Valve
    • 6.3.3 Transcatheter Valve with Hybrid Material
  • 6.4 Transcatheter Valve Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Cardiac Centers
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Specialty Clinics
    • 6.4.5 Online Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Transcatheter Valve Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Transcatheter Valve market is categorized based on

By Product Type

• Transcatheter Aortic Valve
• Transcatheter Mitral Valve
• Transcatheter Pulmonary Valve
• Transcatheter Tricuspid Valve
• Transcatheter Combo Valve

By Application

• Transcatheter Aortic Valve Replacement (TAVR)
• Transcatheter Mitral Valve Repair (TMVR)
• Transcatheter Pulmonary Valve Replacement
• Transcatheter Tricuspid Valve Repair
• Transcatheter Combo Valve Procedures

By Distribution Channel

• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers
• Specialty Clinics
• Online Sales

By Material Type

• Metal Valve
• Tissue Valve
• Transcatheter Valve with Hybrid Material

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Edwards Lifesciences Corporation
• Boston Scientific Corporation
• Medtronic plc
• Abbott Laboratories
• Cardinal Health, Inc.
• JenaValve Technology, Inc.
• Symetis SA
• Micro Interventional Devices, Inc.
• Direct Flow Medical, Inc.
• Neovasc Inc.
• St. Jude Medical, Inc.
• TERUMO Corporation
• Cryolife, Inc.
• Direct Flow Medical, Inc.
• Vascular Innovations